Anti-EGFR Antibody-drug Conjugate CPO301 clinical trials
Also written SYS6010.
Its developmentBy CSPC Pharmaceutical Group and Conjupro Biotherapeutics, step by step16 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-EGFR Antibody-drug Conjugate CPO301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-EGFR Antibody-drug Conjugate CPO301 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (10)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 2
CSPC Megalith Biopharmaceutical Co.,Ltd. (13) · Fujian Cancer Hospital (1) · Sichuan University (1) · Shanghai JMT-Bio Inc. (1) · Conjupro Biotherapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Enlonstobart (4) · ATM Inhibitor SYH2051 (2) · Anti-PD-1/IL-15 Fusion Protein JMT108 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test Anti-EGFR Antibody-drug Conjugate CPO301, phase 3 first.
- Dec 2026A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCPhase 3 · CSPC Megalith Biopharmaceutical Co.,Ltd.
- Sep 2027SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Phase 3 · CSPC Megalith Biopharmaceutical Co.,Ltd.
- Nov 2026A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerPhase 2 · CSPC Megalith Biopharmaceutical Co.,Ltd.
- May 2027A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid TumorsPhase 1 · Conjupro Biotherapeutics, Inc.
- Jun 2027Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsPhase 1/2 · CSPC Megalith Biopharmaceutical Co.,Ltd.
Studies
Open first, then newest update. How each study uses Anti-EGFR Antibody-drug Conjugate CPO301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223Written as SYS6010How we know
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07924111Written as SYS6010How we know
- SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07254585Written as SYS6010 injectionHow we know
- SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCCNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07758621Written as SYS6010How we know
- A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLCNot yet recruitingPhase 1Sichuan UniversityNCT07692048Written as SYS6010How we know
- Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)RecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986Written as SYS6010How we know
- SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07633873Written as SYS6010 injectionHow we know
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07376382Written as SYS6010How we know
- A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1Conjupro Biotherapeutics, Inc.NCT05948865Written as CPO301How we know
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingPhase 1/2Shanghai JMT-Bio Inc.NCT07472647Written as SYS6090 + SYS6010How we know
- SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase ⅢNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07442565Written as SYS6010How we know
- SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07417735Written as SYS6010How we know
- A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast CancerNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07406542Written as SYS6010How we know
- A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509Written as SYS6010How we know
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Not yet recruitingPhase 2/3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07251062Written as SYS6010+SG001How we know
- Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06775236Written as SYS6010 jnjectionHow we know
- A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal TumorsActive, not recruitingNot applicableFujian Cancer HospitalNCT07104877Written as SYS6010How we know
Given beside what is tested · 1 — Anti-EGFR Antibody-drug Conjugate CPO301 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 20, 2026.